Zi-Factor is a trade mark of azithromycin made in Russia by ZAO Veropharm. The in vitro modulating action of Zi-Factor (ZF) on neutrophil functional activity and production of immunity mediators was studied. The direct modulating effect of ZF in a concentration of 50 mcg/ml corresponding to the single therapeutic dose of 500 mg/70 kg body weight on the neutrophil oxidase activity evident from increased production of active oxygen and higher myeloperoxidase activity was shown. The immunomodulating effect of ZF on modulation of intracellular oxidative metabolism depended on the initial state of the phagocyte system (secondary insufficiency or activation). When the neutrophil oxidase system is exhausted and there is no response to the antigen stimulus, it is advisable to combine the use of ZF with immunomodulating therapy.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!